Early initiation of antiretroviral therapy preserves the metabolic function of CD4+ T-cells in subtype C HIV-1 infection

J Infect Dis

This study explores the impact of starting antiretroviral therapy (ART) early on the metabolic function of a specific type of immune cells called CD4+ T-cells in individuals infected with subtype C HIV-1, a common strain of the virus.

The key findings suggest that initiating antiretroviral therapy at an early stage of infection helps to preserve the metabolic function of CD4+ T-cells. CD4+ T-cells play a crucial role in the immune system, and their proper functioning is essential for mounting an effective defense against infections, including HIV.

The significance of this research lies in understanding the importance of timely intervention with antiretroviral therapy. Starting treatment early not only helps in controlling the replication of the virus but also appears to have positive effects on the metabolic function of CD4+ T-cells. This preservation of immune function could contribute to better overall health outcomes for individuals living with HIV.

In practical terms, these findings support the current global recommendations for early initiation of antiretroviral therapy in individuals diagnosed with HIV. By doing so, healthcare providers aim not only to suppress the virus but also to maintain the integrity and effectiveness of the immune system, which is vital for the long-term health of individuals living with HIV.

Disclaimer: This lay summary was generated by AI and has not been approved by any of the authors yet.

SANTHE is an Africa Health Research Institute (AHRI) flagship programme funded by the Science for Africa Foundation through the DELTAS Africa programme; the Bill & Melinda Gates Foundation; Gilead Sciences Inc.; and the Ragon Institute of Mass General, MIT, and Harvard.